JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/70/0.1/21.06.24 Stock JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/70/0.1/21.06.24
Add to a list
To use this feature you must be a member
Log inSign up

JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/70/0.1/21.06.24 Share Price

Warrant

DE000JQ506G5

Market Closed - Börse Stuttgart 02:52:53 11/06/2024 pm IST
0.002 EUR 0.00% Intraday chart for JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/70/0.1/21.06.24
Current month+100.00%
3 months-80.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart BRISTOL-MYERS SQUIBB COMPANY
Chart JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/70/0.1/21.06.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors BU
More news

Quotes 5-day view

Date Price Change
11/24/11 0.002 0.00%

Delayed Quote Börse Stuttgart

Last update June 11, 2024 at 02:52 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BRISTOL-MYERS SQUIBB COMPANY
Issuer J.P. Morgan
WKN JQ506G
ISINDE000JQ506G5
Date issued 23/09/2022
Strike 70 $
Maturity 21/06/2024 (5 Days)
Parity 10 : 1
Emission price 1.04 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.73 €
Lowest since issue 0.001 €
Delta0.02x
Omega 12.69
Premium66.52x
Gearing653.83x
Moneyness 0.6011
Difference Strike 28.8 $
Difference Strike %+41.14%
Spread 0.01 €
Spread %90.91%
Theoretical value 0.006000
Implied Volatility 140.47 %
Total Loss Probability 98.92 %
Intrinsic value 0.000000
Present value 0.006000
Break even 70.06 €
Theta-0.01x
Vega0x
Rho0x

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
-
More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Bristol-Myers Squibb Company

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2 USD
Average target price
53.19 USD
Spread / Average Target
+29.11%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant